Goldman Sachs Downgrades Johnson & Johnson (JNJ) to Sell, Sees Limited Upside

October 9, 2012 7:25 AM EDT Send to a Friend
Get Alerts JNJ Hot Sheet
Price: $99.65 +0.45%

Rating Summary:
    7 Buy, 15 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 13 | New: 40
Trade JNJ Now!
Join SI Premium – FREE
Goldman Sachs downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Sell with a price target of $72.00, saying they see limited upside.

The firm said they only see 7% upside for JNJ, versus 14% average upside for the rest of the group.

"Although JNJ has potential for improved growth, we believe this is already captured
in valuation," the analyst said. "We see JNJ as lacking transformational pipeline opportunities and less inclined to do shareholder-friendly capital allocation."

Goldman upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral, as noted earlier.

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $69.44 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades, Hot Downgrades

Related Entities

Goldman Sachs

Add Your Comment